CClinicalTrials.gg
Not yet recruitingNCT07258381Updated Dec 2, 2025

Mailuo Shutong Pills for Diabetic Wound Healing: A Multicenter Randomized Trial

An interventional study of Mailuo Shutong Pills and Blank control in Diabetic Wound and Chronic Wound Care, sponsored by Peking University Third Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Peking University Third Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Mailuo Shutong Pills are a Chinese patent medicine approved for market release by the China Food and Drug Administration (CFDA) in 2009. It is formulated by integrating five classical herbal formulas, including Ermiao San, Simiao Yongan Tang, and Zhijing San. Its composition is as follows: Honeysuckle Flower (Jinyinhua) serves as the principal component (Jun herb) for clearing heat and detoxifying; Astragalus Root (Huangqi) for tonifying qi, expelling toxin, and promoting diuresis; Phellodendron Bark (Huangbai), Atractylodes Rhizome (Cangzhu), and Coix Seed (Yiyiren) act as deputy components (Chen herbs) to clear heat and resolve dampness; Chinese Angelica (Danggui), Peony Root (Baishao), and Licorice Root (Gancao) alleviate spasm and pain; Figwort Root (Xuanshen) cools the blood, clears heat, drains fire, detoxifies, and softens hard masses. Leeches (Shuizhi), Centipede (Wugong), and Scorpion (Quanxie) serve as assistant components (Zuo herbs) to invigorate blood, resolve stasis, attack toxicity, dissipate nodules, and unblock collaterals to relieve pain. Licorice Root (Gancao) also harmonizes the various components in the formula as the envoy component (Shi herb). The complete formula possesses the effects of clearing heat and detoxifying, dissolving stasis and unblocking collaterals, and dispelling dampness and reducing swelling. It is indicated for various conditions differentiated in Traditional Chinese Medicine (TCM) as presenting with a pattern of dampness-heat and stasis obstruction, such as superficial thrombophlebitis and deep vein thrombosis in the non-acute stage.

Some studies suggest that Mailuo Shutong Pills may have a positive effect in the field of wound healing, for example, by significantly reducing the release of inflammatory mediators such as IL-1β, IL-6, CRP, and TNF-α caused by inflammatory diseases [11-13], and accelerating the healing of diabetic foot wounds [14]. Clinical guidelines, including the "Clinical Application Guide for Chinese Patent Medicines - Diabetes Volume" from the Diabetes Branch of the China Association of Chinese Medicine and the "Integrated Traditional Chinese and Western Medicine Diagnosis and Treatment Guidelines for Diabetic Foot" from the Chinese Medical Doctor Association, recommend Mailuo Shutong Pills for the treatment of diabetic foot ulcers [15]. However, the current related evidence-based medical evidence is insufficient. We have also observed that the adjunctive use of Mailuo Shutong Pills does not guarantee a shortened healing time for all patients with diabetic wounds. From a TCM perspective, the presence of a dampness-heat and stasis obstruction pattern is a key factor determining the efficacy of adjunctive Mailuo Shutong therapy. For Western medicine practitioners, tongue diagnosis presents a practicable factor for assessing pattern manifestation. Therefore, based on differences in patient patterns and using tongue appearance as an inclusion/exclusion criterion, to screen for the indications of Mailuo Shutong Pills combined with existing standard treatment for diabetic wounds constitutes an effective technical approach to address the aforementioned issues.

Consequently, this study aims to explore the indications for Mailuo Shutong Pills in diabetic wounds and obtain evidence-based medical evidence for its clinical efficacy within an integrated Chinese-Western medicine approach. Furthermore, to enhance the study's external validity and participant recruitment efficiency, thereby accelerating the research progress, this study is designed as an exploratory trial conducted across multiple centers.

02

Conditions studied

  • Diabetic Wound
  • Chronic Wound Care

Keywords

  • diabetic wound
  • chronic wound care
03

In context

Lead sponsor

Peking University Third Hospital is the lead sponsor of 735 studies on the registry; 262 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • a confirmed diagnosis of type 1 or type 2 diabetes mellitus;
  • the type of wound is an ulcer, with an ulcer area ranging from 1 to 40cm ²;
  • the wound etiology is diabetic, mainly abnormalities in blood glucose, resulting in poor or prolonged healing and requiring standard wound therapy;
  • The traditional Chinese medicine diagnosis is Damp-Heat Toxin Accumulation Syndrome;
  • voluntary participation in the study and signing of an informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of a Cold Pattern according to Traditional Chinese Medicine (TCM) differentiation, manifested as: pale, enlarged, and tender tongue with a white, moist or glossy coating; pallor; pale lips; aversion to cold with a preference for warmth; and loose stools.
  • Pregnancy or lactation.
  • Presence of severe, uncorrected systemic diseases, such as acute myocardial infarction, heart failure, hepatitis, shock, or respiratory failure.

Active bleeding within the wound that prevents the implementation of standard wound care.

  • Severe laboratory abnormalities: serum albumin \< 20 g/L; hemoglobin \< 60 g/L; or platelet count \< 50 × 10⁹/L.
  • Diagnosis of advanced malignant tumor.
  • Active phase of an autoimmune disease.
  • History of hypersensitivity to Mailuo Shutong Pills or Mailuo Shutong Granules.
  • Inability to cooperate with the study procedures or presence of psychiatric disorders.
  • Any other condition considered by the investigator as a clear, unmodifiable factor adversely affecting wound healing, making the candidate unsuitable for the study or unable to comply with the study requirements.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Based on the clinical standard treatment plan, oral administration of Maoluo Shutong Pills was administered for 2 weeks

    Drug: Mailuo Shutong Pills

  • Sham comparator
    Control group

    the clinical standard treatment plan

    Drug: Blank control

Interventions

  • DrugMailuo Shutong Pills

    a medicine that treating Diabetic Wounds with Damp-Heat Toxin Accumulation Syndrome

  • DrugBlank control

    Blank control

06

What researchers measure

Primary outcomes

  1. wound area reduction rate

    Pre-treatment area minus post-treatment area, then divided by pre-treatment area

    Time frame: Day14 ± 2

Secondary outcomes

  1. wound healing rate

    Percentage of healed wounds to total cases by D14

    Time frame: Day14 ± 2

  2. Granulation tissue status

    They were classified as healthy granulation, inflammatory granulation, infected granulation, oedematous granulation, and aged granulation. D0/D14, wound granulation tissue status was recorded separately

    Time frame: Day 0/Day 14 ± 2

  3. wound infection control

    0 points for no infection, 1 point for reduction of localised infection; 2 points for maintenance or exacerbation of localised infection; 3 points for disseminated infection; record D0/D14, the status of the wound infection and record the scoring results respectively

    Time frame: Day 0/Day 14 ± 2

  4. Tongue appearance

    According to the tongue image photography SOP, record the tongue images

    Time frame: Day 0, Day 7±2 and Day 14±2

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07258381
Lead sponsor
Peking University Third Hospital
Responsible party
Long Zhang (Head of Wound Healing Center, Peking University Third Hospital) — Principal investigator
First posted
Dec 2, 2025
Start date
Dec 1, 2025 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Dec 2, 2025

Study contacts

Long Zhang Executive Deputy Director, Medical Doctor
Contact
longzh2000@163.com
+86 010-82266699

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion